July 20	July 20, 2022		
08:30- 08:45	CASSS Welcome and Introductory Comments Washingtonian Ballroom D-G Bhavin Parekh, Eli Lilly and Company		
08:45- 10:30	Workshop Session One: The Nuts and Bolts of Bioassays Washingtonian Ballroom D-G Session Chairs: Katrin Buss, BfArM, Federal Institute for Drugs and Medical Devices, Jill Crouse-Zeineddini, Amgen Inc., and Thomas Millward, Novartis Pharma AG Session Speakers: Characterizing Antibody Fc Effector Functions by Using SPR and Cell-Based Assays Alexander Berger, Boehringer Ingelheim Pharma GmbH & Co. KG A Better Understanding of Bioassays – How Suitable are Primary Cell Based Assays for the Evaluation of Product Quality		
	Florian Cymer, F. Hoffmann-La Roche Ltd Bioassay Strategies for Challenging Biologics Ganesh Shankarling, Bristol-Myers Squibb Company An Alternative Influenza Vaccine Potency Assay: Assessing Receptor-Binding Hemagglutinin by a Coupled Receptor-binding/RP-HPLC Assay Huixin Lu, Health Canada		
10:30- 11:15	Networking Break Washingtonian Ballroom A-C New Member Networking Event Lakeside Ballroom 1		
11:15- 12:15	Workshop Session I - Panel Discussion Washingtonian Ballroom D-G		
12:15- 13:30	Lunch and Learn: Vendor Showcase Washingtonian Ballroom D-G		
13:30- 14:30	Poster Session Washingtonian Ballroom A-C		
14:30- 16:15	Workshop Session Two: Bioassays for Cell and Gene Therapies Washingtonian Ballroom D-G Session Chairs: Marina Feschenko, Biogen, Xu-Rong Jiang, AstraZeneca BioVentures, Bhavin Parekh, Eli Lilly and Company, and Michael Sadick, Precision Biosciences Session Speakers: Resetting Expectations for CAR-T Potency Assessment Avinash Chinthala, Precision Biosciences Challenges of Developing Potency Assays for Critical Materials Used in Cell and Gene Therapy Products Amanda Dios, Beam Therapeutics Evolution of Potency Strategy for Gene Therapies Edith Nalbandian, Tune Therapeutics Platforms to Accelerate Gene Therapy, Cell-Based Assay Development Katelyn Mansfield, Biogen		
	Additional Panel Member:		

	Ramjay Vatsan, CBER, FDA
16:15- 16:30	Networking Break Washingtonian Ballroom A-C
16:30- 17:30	Workshop Session Two - Panel Discussion Washingtonian Ballroom D-G
17:30- 18:30	Exhibitor and Poster Reception Washingtonian Ballroom A-C

July 21, 2022		
08:30- 09:15	Keynote Presentation Washingtonian Ballroom D-G Bioassays Throughout Drug Development and the Product Life Cycle Marjorie Shapiro, CDER, FDA	
09:15- 09:30	Networking Break Washingtonian Ballroom A-C	
09:30- 11:15	Workshop Session Three: Bioassays for Vaccines Washingtonian Ballroom D-G Session Chairs: David Cirelli, Pfizer, Inc. and Martin Nemec, Health Canada Session Speakers: Bioassay Technologies for mRNA Vaccines Emma Reyes, Pfizer, Inc. Improving a Vaccine Potency Assay – A Real World Regulatory Implementation Saga Kimberly Duffy, Merck & Co. Inc. From Bioassay Method Development to Commercial Testing at Pandemic Speed: The Story of AZD1222 (ChAdOx1 nCoV-19) Scott Umlauf, AstraZeneca Bioassay Points to Consider During a Pandemic: A Regulator's Perspective Jason Fernandes, Health Canada	
11:15- 11:45	Networking Break Washingtonian Ballroom A-C	
11:45- 12:45	Workshop Session Three - Panel Discussion Washingtonian Ballroom D-G	
12:45- 13:45	Hosted Lunch Washingtonian Ballroom Foyer	
13:45- 15:30	Workshop Session Four: Process Improvements & Innovation in Bioassays Washingtonian Ballroom D-G Session Chairs: Chana Fuchs, CDER, FDA, Stephen Hartman, AbbVie Inc. and Adelheid Rohde, F. Hoffmann - La Roche Ltd.	

	Session Speakers: Phase-Appropriate Potency Assay Development Strategies for Gene Therapy Products Arkadi Manukyan, Sanofi Selection of Optimal 4PL Dose Response Curves Using a Computational Simulation Method Ahmad Ebtikar, Genentech, a Member of the Roche Group Characterization of Dual AAV Vector Otoferlin Christine Le Bec, Sensorion CD107a Degranulation Assay to Measure CAR-T Potency Cynthia Bamdad, Minerva Biotechnologies
15:30- 15:45	Networking Break Washingtonian Ballroom Foyer
15:45- 16:45	Workshop Session Four - Panel Discussion Washingtonian Ballroom D-G
16:45- 17:00	Closing Remarks Washingtonian Ballroom D-G David Cirelli, <i>Pfizer, Inc.</i>